Caro G, Getsios D, Caro J J, Raggio G, Burrows M, Black L
Caro Research, Montreal, QC, Canada.
Cephalalgia. 2001 Feb;21(1):12-9. doi: 10.1046/j.1468-2982.2001.00130.x.
The objective of this study was to evaluate economic and health effects of sumatriptan relative to customary therapy in Canada. The relationship between treatment and functionality was established based on analysis of existing data from a multinational study. A Monte Carlo model was developed to simulate 1 year for each of customary therapy and six sumatriptan formulations. Costs are expressed in 1998 Canadian dollars. Sumatriptan is expected to reduce the time spent with migraine symptoms and resulting time lost. Under customary therapy, the annual cost of lost time is estimated at pound908 ($1973). With sumatriptan, these costs ranged from pound406 ($882) with subcutaneous sumatriptan to pound577 ($1254) with nasal sumatriptan 10 mg, saving pound331-502 ($719-1091) in the annual cost of time lost. All these benefits are expected to be obtained at an additional drug cost ranging from pound869 ($1889) for subcutaneous sumatriptan to pound278 ($605) for sumatriptan suppository. The cost of sumatriptan treatment is significantly offset by a substantial reduction of costs associated with time lost due to migraine symptoms.
本研究的目的是评估在加拿大，舒马曲坦相对于传统疗法的经济和健康影响。基于对一项跨国研究现有数据的分析，确定了治疗与功能之间的关系。开发了一个蒙特卡洛模型，对传统疗法和六种舒马曲坦制剂各模拟1年的情况。成本以1998年加拿大元表示。预计舒马曲坦可减少偏头痛症状持续的时间以及由此导致的时间损失。在传统疗法下，每年因时间损失造成的成本估计为908英镑（1973美元）。使用舒马曲坦时，这些成本从皮下注射舒马曲坦的406英镑（882美元）到10毫克鼻用舒马曲坦的577英镑（1254美元）不等，每年因时间损失造成的成本节省了331 - 502英镑（719 - 1091美元）。预计所有这些益处都是在额外药物成本的基础上获得的，额外药物成本从皮下注射舒马曲坦的869英镑（1889美元）到舒马曲坦栓剂的278英镑（605美元）不等。舒马曲坦治疗的成本因偏头痛症状导致的时间损失相关成本大幅降低而得到显著抵消。
